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Background: Helicobacter pylori infection is a world-wide common disease and
leads to many gastrointestinal and respiratory illnesses. It is suggested that one of
these respiratory illnesses is lung cancer.
Methods: Forty-three patients with non-small cell lung cancer and 28 control
subjects have been included to this study. H. pylori status of the patients and
controls was determined by immunoblot for the detection of IgG (RIDA Blot
Helicobacter). All subjects were examined to evaluate the presence of VacA and
CagA gene.
Results: Seropositivity of anti H. pylori IgG was significantly higher in cancer
patients than in control groups, 40 (93%) and 12 (42%), respectively (Po0:01).
Although both VacA and CagA seropositivity was high in lung cancer patients, only
VacA positivity was statistically significant when compared with control subjects, 35
(81%) and 11 (42%), respectively (Po0:05).
Conclusion: H. pylori infection may be associated with development of lung cancer.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Lung cancer is one of the most common causes of
mortality in the world. During the last 50 years, its
incidence is dramatically increasing, not only in
men but also in women. It is one of the few human
cancers whose carcinogen is known. The incidence
of lung cancer has been strongly linked to cigaretteElsevier Ltd. All rights reserv
473 6633.
m (F. Ece).smoking. It also occurs in association with occupa-
tional and environmental exposure to carcinogenic
agents. There are some other factors related to the
development of lung cancer such as familial
predisposition, genetic alteration, and more re-
cently Helicobacter pylori infection.1–3 H. pylori is
a Gram-negative, spiral-shaped bacterium. The
phenotypic differences between H. pylori isolates
are production or non-production of a vacuolating
cytotoxin, VacA, and a cytotoxin associated pro-
tein, CagA.4,5 H. pylori strains of type I have theed.
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which do not have this ability belong to type II.
Type I infections lead to more serious illnesses.6
The International Agency for Research on Cancer of
the World Health Organization recommends that H.
pylori be classified as a group I carcinogen.7 It has
been showed that H. pylori infection may con-
tribute to lung cancerogenesis via upregulation of
gastrin and COX-2 that may account for the
stimulation of tumor growth and angiogenesis.3
The aim of this study was to determine the VacA,
and CagA genotypes of H. pylori in patients with
lung cancer and healthy controls, and compare the
values of these two groups in an effort to elucidate
a potential causative relationship.Materials and methods
Study subjects
Forty-three histologically verified non-small cell
lung cancer (NSCLC) patients and 28 controls, who
were current smokers, were enrolled in the study.
Lung carcinoma diagnosis was achieved by fiber-
optic bronchoscopy and/or transthoracic needle
aspiration. Controls were selected randomly from
healthy patient family members. All subjects,
controls and cancer patients, had neither gastric
symptoms nor diagnosis of gastric cancer, peptic
ulcer, or chronic gastritis.
Methods
H. pylori status was determined by immunoblot for
the detection of IgG (RIDA Blot Helicobacter [R-
Biopharm GmbH, Darmstadt, Germany]). We took
5 cm3 blood specimen from each patient beforeTable 1 Point values of the antigens in the RIDA blot He
Molecular weight (kD) Antigen
120 CagA
87 VacA
67 OMP 67
62 Urease B
58 Heat shock protein
54 Flagellin
47 —
33 —
29 Urease A
28 —
25 —
19 —starting chemotherapy and from controls, and
stored the sera at 70 1C. All materials were kept
at room temperature for at least 30min prior to
use. Antigens of VacA and CagA positive isolates of
H. pylori were separated electrophoretically by
their molecular weight. They were blotted on a
nitrocellulose membrane. The membrane was cut
into single strips. These strips would be incubated
with the samples (serum). Specific antibodies
present in the samples would bind to the corre-
sponding protein bands on the strip. After removing
the unbound antibodies by washing, a second
incubation with anti-human IgG conjugate fol-
lowed. In a last step (staining reaction), specifically
bound antibodies against the different H. pylori
antigens become visible as blue bands on the strips.
To evaluate a specimen, the incubation control
band of the test strips were lined up with the
control band of the strip of the evaluation
template. With the kD statements of the evaluation
template, the visible bands of the patient samples
could be identified.8 The bands received point
values which were determined depending on the
meaning of the bands and their detected immu-
noglobulin class. The evaluation of the sample was
undertaken with regard to the total point value.
The point values of the antigen bands in the IgG
test which were determined with mathematical
analyses, are listed in Table 1. A serum was IgG-
positive if the total point number was larger than
12. It was IgG-negative if the total point number
was smaller than 11.Analysis
Statistical analysis was done by using GraphPad
Prisma V3 program. Independent t-test was used
for the comparison of groups and w2 for thelicobacter IgG.
Function Point value
Cytotoxin associated protein 5
Vacuolating cytotoxin 5
Unknown 2
Large subunit of urease 1
Stress protein 1
Flagellin 2
Unknown 5
Unknown 5
Small subunit of urease 3
Unknown 4
Unknown 4
Unknown 5
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was accepted as statistically significant.Results
A total of 43 patients with NSCLC were included in
this study. There were 35 males and eight females
with a mean age of 56711 years. Twenty-two of
them had squamous cell lung cancer and 21 had
adenocarcinoma. Characteristics of the patients
are shown in Table 2. The control group consisted of
28 healthy subjects with no gastric complaints.
Twenty-two of them were male and six were female
with a mean age of 5479 years. Patient and control
groups were comparable. There were no statistical
differences in age, gender, smoking habit (pack/
year) or socioeconomic status between the two
groups. Seropositivity of anti-H. pylori IgG was
significantly higher in cancer patients than in
control groups, IgG values were 21.2878.01 for
cancer patients and 13.8077.59 for controls
(Po0:01). Prevalence of CagA and VacA seroposi-
tivity reached 80% in lung cancer but only 40% in
controls and this difference between cancer pa-
tients and controls was statistically significant
(Po0:05). Seropositivity of anti-H. pylori IgG in
squamous lung cancer and adenocarcinoma pa-
tients were significantly higher than control sub-Table 2 Characteristics of the patients.
Squamous Adenoca
n (%) n (%)
Sex
Male 21 (95.5) 14 (66.7)
Female 1 (4.5) 7 (33.3)
Stage
III B 13 (59.1) 16 (76.2)
IV 9 (40.9) 5 (23.8)
PS
0 11 (50) 15 (71.4)
1 11 (50) 6 (28.6)
Table 3 Comparison of seropositivity of controls and pa
Squamous Adenoca
Total IgG value (mean7SD) 22.2778.48 20.2477.5
IgG+[n(%)] 20 (90.90) 20(95.2
CagA+[n(%)] 18 (81.8) 18 (85.7
VacA+[n(%)] 18 (81.8) 17 (81)
Sq: squamous cell lung cancer, Ad: adenocarcinoma, Cont: controjects. Although both VacA and CagA seropositivity
was high in lung cancer patients, only VacA
positivity was statistically significant when com-
pared with control subjects (Table 3). There were
no significant differences in the prevalence of H.
pylori between squamous lung cancer and adeno-
carcinoma patients (Fig. 1).Discussion
H. pylori has become a world-wide infective agent
ranging from 25% in developed countries to more
than 80% in the developing world.9 It is known that
H. pylori infection has an important role in the
development of chronic gastritis, peptic ulcer,
gastric mucosa-associated lymphoid tissue (MALT-
lymphoma), and gastric cancer.10–13 It has also been
shown that H. pylori infection leads to many
respiratory illnesses as well.14 This study demon-
strates that lung cancer is associated with H. pylori
infection. It has been reported that H. pylori
infection with type I strain, which expresses the
VacA and CagA antigen, is associated with more
serious illnesses.6 In our study, H. pylori seroposi-
tivity was significantly higher in cancer patients
than in control subjects. Also more lung cancer
cases were CagA- and VacA- positive patients than
controls; however, only VacA seropositivity showedtients according to histopathology.
Control Gr P (Sq vs cont) P (Ad vs cont)
6 13.8077.59 o0.01 o0.01
3) 12(42.85) o0.01 o0.01
) 18 (64.28) 40.05 40.05
11 (42) o0.05 o0.05
l group
Squamous Adeno Ca
100
80
60
40
20
0
Tot. lg G + CagA+(%) VacA+(%)
Figure 1 Seropositivity levels according to histopathol-
ogy of tumor.
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study reported that CagA strain seropositivity in
lung cancer patients was about thrice as high as in
controls (63% vs. 21.5%, respectively, Po0:05).3
Determination of the VacA and CagA gene together
may contribute to delineation of patients who have
different levels of risk. It has been put forward that
CagA plays a partial role in increased mucosal
inflammation, increased density of H. pylori in
antrum, and causes more profound inhibition of
mucin synthesis, duodenal ulcer, gastric ulcer and
gastric cancer.15 Many risk factors have been
determined for H. pylori infection (CagA, VacA,
IceA etc.), but none of them is specific for
disease.16 The opinion that VacA genotyping might
be clinically useful, e.g. to predict presentation
such as duodenal ulcer, has been proven wrong.17
Virulence is a host-dependent factor. For instance,
CagA-positive H. pylori strain is common in Thai
patients with gastroduodenal diseases.18 In our
study, VacA seropositivity was significantly high in
lung cancer patients. The reason for the higher
prevalence of H. pylori infection in the lung cancer
patients is not apparent but the fact that the
majority of cancer patients were smokers, who are
known to have higher H. pylori infection rate.19,20
Although smoking is thought to be related to H.
pylori infection, some studies, supporting our
findings, showed no significant relation between
H. pylori seroconversion and smoking.21 In Turkish
population, smoking rate is high, the per capita
yearly cigarette consumption over the age of 15
increased from 1850 in 1965 to 2600 in 1992.22 In
our study, control subjects as well as cancer
patients were smokers; however, H. pylori seropo-
sitivity was significantly lower in control subjects
than cancer patients. So H. pylori infection by itself
may be a risk factor for lung cancer. Lungs arise
embriologically from the same endodermal cells
that form the lining of the gastrointestinal tract
and possess similar cells releasing various hormonal
peptides.23 Increased plasma level of gastrin which
is accompanied by H. pylori infection may con-
tribute to the lung cancerogenesis by inducing
mucosal cell proliferation of bronchial epithe-
lium.24 In the study done by Zhou et al.25 it has
been shown that serum from patients with lung
cancer contained a high concentration of gastrin,
and serum gastrin was found to decrease gradually
after the removal of the tumor and to return to
normal on the 14th postoperative day. In contrast,
a study conducted by Dowlati et al.26 demonstrated
no evidence of clinical usefulness for gastrin
measurements in lung cancer. There was no
correlation with the stage of tumor and gastrin
levels in the serum. Likewise in a study done toshow seroprevalence results in Greek population,
H. pylori seropositivity did not differ significantly
between patients with lung cancer and controls.27
Our results suggest that H. pylori infection may
be associated with the development of lung cancer.
However, further studies with larger numbers of
patients are needed to further elucidate the
potential pathogenetic relationship between H.
pylori infections and lung cancer.References
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